REGENXBIO Inc. (NASDAQ:RGNX) on Saturday shared long-term clinical trial findings for its experimental gene therapy surabgene lomparvovec (sura-vec, ABBV-RGX-314) targeting wet age-related macular degeneration (wet AMD) and diabetic retinopathy (DR).
Long-Term Efficacy In Wet AMD Treatment
Data presented at the American Society of Retina Specialists Annual Meeting demonstrated that subretinal delivery of sura-vec maintained or enhanced visual acuity over five years in wet AMD patients within Cohorts 3 and 4 of its Phase 1/2a trial.
Read Next
Trading Ideas
